Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma

References

• Mina AA, Vakkalagadda C, Pro B. Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy. Cancers (Basel). 2019;11(3):421.
   Web of Science ®Google Scholar
• Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–5504.
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Chinese guidelines for diagnosis and treatment of malignant lymphoma. 2018 (English version). Chin J Cancer Res. 2019;31(4):557–577.
   Google Scholar
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89(3):801–813.
   PubMed Web of Science ®Google Scholar
• Kleiner S, Kirsch A, Schwaner I, et al. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Bone Marrow Transplant. 1997;20(11):953–959.
   PubMed Web of Science ®Google Scholar
• Bennani-Baiti N, Ansell S, Feldman AL. Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management. Expert Rev Hematol. 2016;9(2):137–150.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071.
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–1566.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al., Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709–2717.
   PubMed Web of Science ®Google Scholar
• Van Der Weyden CA, Pileri SA, Feldman AL, et al. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017;7(9):e603.
   PubMed Web of Science ®Google Scholar
• Suri A, Mould DR, Liu Y, et al. Population PK and exposure-response relationships for the antibody-drug conjugate brentuximab vedotin in CTCL patients in the Phase III ALCANZA study. Clin Pharmacol Ther. 2018;104(5):989–999.
   PubMed Web of Science ®Google Scholar
• Bradley AM, Devine M, DeRemer D. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. Am J Health Syst Pharm. 2013;70(7):589–597.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 [Internet] 2010 [cited 2020 Oct 14]. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
   Google Scholar
• Ogura M, Tobinai K, Hatake K, et al. Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105(7):840–846.
   PubMed Web of Science ®Google Scholar
• Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol. 2000;18(13):2615–2619.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease patients. Haematologica. 2000;85(9):926–929.
   PubMed Web of Science ®Google Scholar
• Venkatesh H, Di Bella N, Flynn TP, et al. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma. Clin Lymphoma. 2004;5(2):110–115.
   PubMedGoogle Scholar
• Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008;112(4):831–836.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. ADCETRIS® (brentuximab vedotin) summary of product characteristics [Internet] 2018 [cited 2020 Oct 14]. Available from: https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf.
   Google Scholar
• ADCETRIS® (brentuximab vedotin) for injection, for intravenous use [prescribing information]. Bothell, WA: Seattle Genetics Inc. 2019.
   Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al., Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196.
   PubMed Web of Science ®Google Scholar
• Suri A, Mould DR, Song G, et al. Population pharmacokinetic modeling and exposure-response assessment for the antibody-drug conjugate brentuximab vedotin in Hodgkin’s lymphoma in the Phase III ECHELON-1 study. Clin Pharmacol Ther. 2019;106(6):1268–1279.
   PubMed Web of Science ®Google Scholar